By Adedapo Adesanya
Aide Health, a London, UK-based health-tech startup, has raised £1 million in pre-seed funding.
The round was led by Hambro Perks through its EIS fund, with participation from Fuel Ventures, 1818 Ventures and APX Ventures.
In a statement made available to Business Post on Friday, the company intends to use the funds to expand its services to include hypertension and chronic pain.
Co-founded by Mr Ian Wharton (CEO) and Mr Brian Snyde, Aide Health is a digital platform that helps patients and their clinicians understand and manage long-term health conditions, such as type-2 diabetes, heart disease, asthma, and IBD, paired with a mobile app for the patient which acts as a co-pilot through their care.
Medical professionals can use Aide Health’s platform to remotely monitor patients with chronic diseases such as type-2 diabetes, heart disease, asthma, and IBD. Patients monitored through the app can also receive medical advice.
“Like many people, I know first-hand the frustrations of trying to manage long-term conditions,” said Mr Wharton, CEO of Aide Health.
“Our goal is to give both patients and clinicians the tools and insights they need to have better conversations and make more informed treatment decisions together,” he added.
On his part, Mr Nicholas Sharp, head of the Hambro Perks Growth EIS Fund, said: “Ian and Brian’s vision and experience impressed us from the start, and we believe that Aide Health has the potential to be a hugely important tool for both clinicians and patients for managing long-term health conditions.”
Using natural language, Aide Health has short, daily conversations to help with the day-to-day management of health conditions through medicines optimisation, structured monitoring and structured education.
The service is currently being used by the UK National Health Scheme (NHS), with a pilot launched earlier this year supporting people aged between 18-75 with asthma or type-2 diabetes.
